Literature DB >> 12609675

Simultaneous determination of montelukast and loratadine by HPLC and derivative spectrophotometric methods.

T Radhakrishna1, A Narasaraju, M Ramakrishna, A Satyanarayana.   

Abstract

In this study, high performance liquid chromatography (HPLC) and second derivative spectrophotometry have been used and described for the simultaneous determination of montelukast and loratadine in pharmaceutical formulations. HPLC separation was achieved with a Symmetry C18 column and sodium phosphate buffer (pH adjusted to 3.7): acetonitrile (20:80, v/v) as eluent, at a flow rate of 1.0 ml/min. UV detection was performed at 225 nm. The LC method is simple, rapid, selective and stability indicating for the determination of montelukast. 5-Methyl 2-nitrophenol was used as internal standard for the purpose of quantification of both the drugs in HPLC. In the second-order derivative spectrophotometry, for the determination of loratadine the zero-crossing technique was applied at 276.1 nm, but for montelukast peak amplitude at 359.7 nm (tangent method) was used. Both methods were fully validated and a comparison was made for assay determination of selected drugs in formulations. The results confirm that the methods are highly suitable for its intended purpose.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609675     DOI: 10.1016/s0731-7085(02)00650-7

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

1.  Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.

Authors:  Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Mikko Niemi; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-05-03       Impact factor: 2.953

2.  Determination of Montelukast Sodium and Bambuterol Hydrochloride in Tablets using RP HPLC.

Authors:  Smita Patil; Y V Pore; B S Kuchekar; Aruna Mane; V G Khire
Journal:  Indian J Pharm Sci       Date:  2009-01       Impact factor: 0.975

3.  Development and Validation of a RP-HPLC Method for Estimation of Montelukast Sodium in Bulk and in Tablet Dosage Form.

Authors:  R M Singh; P K Saini; S C Mathur; G N Singh; B Lal
Journal:  Indian J Pharm Sci       Date:  2010-03       Impact factor: 0.975

4.  Method development and validation of montelukast in human plasma by HPLC coupled with ESI-MS/MS: application to a bioequivalence study.

Authors:  Balasekhara Reddy Challa; Bahlul Z Awen; Babu Rao Chandu; Mukkanti Khagga; Chandrasekhar Bannoth Kotthapalli
Journal:  Sci Pharm       Date:  2010-06-04

5.  Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Montelukast Sodium and Ebastine in Tablet Dosage Form.

Authors:  N S Rana; K S Rajesh; Nikita N Patel; P R Patel; U Limbachiya; T Y Pasha
Journal:  Indian J Pharm Sci       Date:  2013-09       Impact factor: 0.975

6.  HPTLC-Densitometric Determination of Cetirizine and Montelukast Analysis in Combined Tablet Dosage Forms.

Authors:  Saeed Haghighi; Mahmoud Reza Shapouri; Mitra Amoli-Diva; Kamyar Pourghazi; Hossein Afruzi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

7.  UV-Vis Spectrophotometry and Multivariate Calibration Method for Simultaneous Determination of Theophylline, Montelukast and Loratadine in Tablet Preparations and Spiked Human Plasma.

Authors:  Seyed Karim Hassaninejad-Darzi; Abdolraouf Samadi-Maybodi; Seyed Mohsen Nikou
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

8.  High performance liquid chromatographic method development for simultaneous analysis of doxofylline and montelukast sodium in a combined form.

Authors:  R Revathi; T Ethiraj; P Thenmozhi; V S Saravanan; V Ganesan
Journal:  Pharm Methods       Date:  2011-10

9.  Stability-indicating HPLC Method for Simultaneous Determination of Montelukast and Fexofenadine Hydrochloride.

Authors:  Mona Pankhaniya; Parula Patel; J S Shah
Journal:  Indian J Pharm Sci       Date:  2013-05       Impact factor: 0.975

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.